**Table S1. Frequency of Local Reactions per Maximum Severity Assessment.**

|  | | Placebo | | | Ad35-GRIN/ENV (2x109 vp) | | | Ad35-GRIN/ENV (2x1010 vp) | | | Ad35-GRIN/ENV (2x1011 vp) | | | Ad35-GRIN (1x1010 vp) | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | Vac1 | Vac2 | Cumulative | Vac1 | Vac2 | Cumulative | Vac1 | Vac2 | Cumulative | Vac1 | Vac2 | Cumulative | Vac1 | Vac2 | Cumulative |
|  | | N=16 | N=16 | N=16 | N=10 | N=9 | N=10 | N=10 | N=8 | N=10 | N=10 | N=9 | N=10 | N=10 | N=8 | N=10 |
| Maximum Reaction | Mild | 7 (43.8%) | 6 (37.5%) | 10 (62.5%) | 5 (50.0%) | 4 (44.4%) | 5 (50.0%) | 8 (80.0%) | 4 (50.0%) | 5 (50.0%) | 4 (40.0%) | 4 (44.4%) | 3 (30.0%) | 9 (90.0%) | 6 (75.0%) | 7 (70.0%) |
|  | Moderate | 1 (6.3%) | 2 (12.5%) | 3 (18.8%) | 1 (10.0%) | 2 (22.2%) | 2 (20.0%) | 1 (10.0%) | 3 (37.5%) | 4 (40.0%) | 4 (40.0%) | 3 (33.3%) | 4 (40.0%) | 1 (10.0%) | 2 (25.0%) | 3 (30.0%) |
|  | Severe | 0 | 0 | 0 | 0 | 1 (11.1%) | 1 (10.0%) | 0 | 1 (12.5%) | 1 (10.0%) | 2 (20.0%) | 2 (22.2%) | 3 (30.0%) | 0 | 0 | 0 |
| Pain | Mild | 5 (31.3%) | 5 (31.3%) | 9 (56.3%) | 2 (20.0%) | 5 (55.6%) | 5 (50.0%) | 7 (70.0%) | 4 (50.0%) | 6 (60.0%) | 6 (60.0%) | 3 (33.3%) | 6 (60.0%) | 9 (90.0%) | 6 (75.0%) | 9 (90.0%) |
|  | Moderate | 1 (6.3%) | 1 (6.3%) | 2 (12.5%) | 1 (10.0%) | 0 | 0 | 1 (10.0%) | 1 (12.5%) | 2 (20.0%) | 1 (10.0%) | 3 (33.3%) | 2 (20.0%) | 1 (10.0%) | 0 | 1 (10.0%) |
|  | Severe | 0 | 0 | 0 | 0 | 1 (11.1%) | 1 (10.0%) | 0 | 1 (12.5%) | 1 (10.0%) | 2 (20.0%) | 0 | 2 (20.0%) | 0 | 0 | 0 |
| Tenderness | Mild | 6 (37.5%) | 6 (37.5%) | 9 (56.3%) | 4 (40.0%) | 4 (44.4%) | 5 (50.0%) | 8 (80.0%) | 5 (62.5%) | 6 (60.0%) | 4 (40.0%) | 5 (55.6%) | 3 (30.0%) | 7 (70.0%) | 6 (75.0%) | 6 (60.0%) |
|  | Moderate | 0 | 1 (6.3%) | 1 (6.3%) | 0 | 2 (22.2%) | 2 (20.0%) | 1 (10.0%) | 3 (37.5%) | 4 (40.0%) | 4 (40.0%) | 2 (22.2%) | 4 (40.0%) | 1 (10.0%) | 2 (25.0%) | 3 (30.0%) |
|  | Severe | 0 | 0 | 0 | 0 | 1 (11.1%) | 1 (10.0%) | 0 | 0 | 0 | 2 (20.0%) | 2 (22.2%) | 3 (30.0%) | 0 | 0 | 0 |
| Erythema\* | Present | 1 (6.3%) | 0 | 1 (6.3%) | 0 | 2 (22.2%) | 2 (20.0%) | 0 | 1 (12.5%) | 1 (10.0%) | 1 (10.0%) | 0 | 1 (10.0%) | 1 (10.0%) | 1 (12.5%) | 0 |
|  | Mild | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 (25.0%) | 2 (20.0%) | 0 | 0 | 0 | 1 (10.0%) | 1 (12.5%) | 2 (20.0%) |
|  | Moderate | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 (12.5%) | 1 (10.0%) | 0 | 2 (22.2%) | 2 (20.0%) | 0 | 0 | 0 |
| Induration | Present | 0 | 0 | 0 | 0 | 1 (11.1%) | 1 (10.0%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Crust or Scab | Present | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 (12.5%) | 1 (10.0%) | 0 | 0 | 0 | 1 (10.0%) | 0 | 1 (10.0%) |

Vac1: First vaccination at Day 0

Vac2:Second Vaccination at Month 6

Present: For erythema/skin discoloration\* and induration, a reaction is considered ‘present’ if the corresponding measurement is less than the criteria for mild. For formation of crust or scab, any measured reaction is considered ‘present’ as there is no toxicity table grading used for this reaction.